Hypertrophic cardiomyopathy (HCM) is an under-recognized, common, and treatable genetic disease occurring worldwide. HCM is a myocardial disorder most often caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus of the heart. It is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Adding to the burden of disease, HCM can present with a variety of symptoms mimicking other conditions and may go undiagnosed for many years and it is estimated that approximately one in 500 individuals in the United States may have clinically unrecognized, undiagnosed HCM, with an overall prevalence estimated at 750,000.
Please join Dr. Maron and Dr. Torres in this first installment of a CMEO Snack series as they discuss strategies for optimal screening of HCM in an effort to increase recognition and diagnosis of this too often misdiagnosed disease.
At the end of this CME/CE activity, participants should be able to screen appropriate patients for HCM using evidence-based diagnostic strategies.
Supported by an educational grant from Bristol Myers Squibb.
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists)
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Maron reports the following financial relationships: Advisory Board: Cytokenetics (REDWOOD-HCM Steering Committee). Consultant: Imbria and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Torres reports no financial relationships.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).